Oxurion Terminates French CRO Acquisition and Pivots to International Multi-Region CRO Target

• Oxurion NV (Euronext Brussels: OXUR), a Leuven-based biopharmaceutical company repositioning as an acquirer of European pharmaceutical subcontractors, has formally terminated discussions for the proposed majority-stake acquisition of a French CRO, following an extensive due diligence process that concluded the conditions required to finalize the transaction were not met.

• Oxurion is now concentrating exclusively on a second acquisition target — an international CRO operating across Europe, North Africa, and the Middle East — as the company advances its strategy to build an integrated clinical research platform combining multi-country operational expertise with advanced clinical data science solutions.

Oxurion NV (Euronext Brussels: OXUR), a Leuven, Belgium-based company specializing in acquiring majority stakes in European pharmaceutical subcontractors, announced on June 1, 2026, that it has terminated discussions regarding the proposed acquisition of a majority stake in a French CRO. The transaction was first disclosed on October 13, 2025, and subsequently extended on February 27, 2026, following initial due diligence activity. Oxurion has now concluded that the conditions required to finalize the transaction in a manner aligned with the Group’s strategic and financial interests were not satisfied.

The termination follows an extensive due diligence process conducted over several months to analyze the French target’s corporate structure and validate its business plan. While Oxurion has not disclosed the identity of the French CRO or the specific findings that led to the decision, the company stated that the threshold conditions for a satisfactory transaction were not met. The outcome represents the conclusion of a process that had been underway for over seven months since the original Letter of Intent was signed.

Oxurion is now directing its full resources toward a separate, and more advanced, acquisition target. The company is in exclusive discussions regarding the proposed majority-stake acquisition of an international CRO operating across Europe, North Africa, and the Middle East — a transaction first announced on March 19, 2026. The international target’s broader geographic footprint and multi-region operational scope appear to align more directly with Oxurion’s stated ambition to build a leading integrated clinical research platform with multi-country capabilities.

The strategic rationale underlying both acquisition discussions reflects Oxurion’s pivot away from its legacy biopharmaceutical drug development focus toward a CRO consolidation model. The company has reframed its corporate identity around acquiring and integrating European pharmaceutical subcontractors, with clinical data science capabilities positioned as a differentiating layer within the broader platform. The international CRO target — covering a corridor that spans Western Europe through North Africa and the Middle East — would give Oxurion access to a geographically diversified CRO operating model at the outset of its platform-building strategy.

“Following extensive due diligence conducted over the past months to analyze the target company’s structure and validate its business plan, Oxurion concluded that the conditions required to finalize the transaction in a satisfactory manner, aligned with the Group’s strategic and financial interests, were not met.”

Oxurion Official Statement